Loading...
OTCM
MYMX
Market cap91kUSD
Mar 28, Last price  
0.00USD
Name

Mymetics Corp

Chart & Performance

D1W1MN
P/E
—
P/S
27.82
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
-71.20%
Revenues
3k
0.00%
0000468,44965,000150,000222,000176,00004,381,0002,399,0003,151,0001,253,0001,515,00075,000111,00035,0003,0003,000
Net income
-8m
L+9.97%
000-984,997-5,624,134-6,938,000-10,186,000-11,428,000-10,539,000-6,111,0006,003,000-3,256,000-3,006,000-5,964,000-4,112,000-4,172,000-4,187,000-4,158,000-7,152,000-7,865,000
CFO
-2m
L-0.65%
00000-7,718,000-11,046,000-7,870,000-5,223,000-4,959,000-4,344,0002,968,000730,000-987,000-2,451,000-2,313,000-972,000-1,696,000-1,698,000-1,687,000

Profile

Mymetics Corporation, a vaccine company, engages in the research and development of vaccines for infectious and life disabling diseases in Switzerland. The company's product pipeline includes various vaccine candidates, such as HIV-1/AIDS, Covid-19, intra nasal influenza, respiratory syncytial virus, malaria, and chikungunya. Mymetics Corporation has a collaboration agreement with Texas Biomedical Research Institute; PATH Malaria Vaccine Initiative and the Laboratory of Malaria Immunology and Vaccinology of the National Institute of Allergy and Infectious Diseases to develop and produce virosome based vaccine formulations for a malaria transmission-blocking vaccine candidate; and Sanofi Pasteur Biologics, LLC to investigate the immunogenicity of influenza vaccines. The company was formerly known as ICHOR Corporation and changed its name to Mymetics Corporation in July 2001. Mymetics Corporation was founded in 1990 and is based in Epalinges, Switzerland.
URL
https://www.mymetics.com/
IPO date
Feb 10, 1995
Employees
2
Domiciled in
CH
Incorporated in
US

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
3
0.00%
Cost of revenue
4,289
Unusual Expense (Income)
NOPBT
(4,286)
NOPBT Margin
Operating Taxes
3,060
Tax Rate
NOPAT
(7,346)
Net income
(7,865)
9.97%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
71,810
Long-term debt
324
Deferred revenue
Other long-term liabilities
Net debt
71,821
Cash flow
Cash from operating activities
(1,687)
CAPEX
(2)
Cash from investing activities
(2)
Cash from financing activities
1,436
FCF
(7,172)
Balance
Cash
313
Long term investments
Excess cash
313
Stockholders' equity
(99,339)
Invested Capital
107,433
ROIC
ROCE
EV
Common stock shares outstanding
303,758
Price
0.03
-9.09%
Market cap
9,113
-9.09%
EV
80,934
EBITDA
(4,271)
EV/EBITDA
Interest
2,800
Interest/NOPBT